D.E. Shaw & Co’s GSK GSK Stock Holding History

D.E. Shaw & Co’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.49M	Buy	66,600 +37,500	+129%	+$1.98M	﹤0.01%	2706
2026 Q1	$1.61M	Buy	+29,100	New	+$1.58M	﹤0.01%	3090
2025 Q2	–	Sell	-102,700	Closed	-$3.98M	–	4482
2025 Q1	$3.98M	Buy	+102,700	New	+$3.76M	﹤0.01%	2072
2021 Q2	–	Sell	-40,000	Closed	-$1.78M	–	4849
2021 Q1	$1.78M	Buy	+40,000	New	+$1.82M	﹤0.01%	2681
2019 Q1	–	Sell	-10,160	Closed	-$485K	–	3718
2018 Q4	$485K	Hold	10,160	–	–	﹤0.01%	3104
2018 Q3	$510K	Hold	10,160	–	–	﹤0.01%	3103
2018 Q2	$512K	Sell	10,160 -24,000	-70%	-$1.21M	﹤0.01%	3105
2018 Q1	$1.67M	Buy	34,160 +10,160	+42%	+$473K	﹤0.01%	2169
2017 Q4	$1.06M	Buy	+24,000	New	+$1.11M	﹤0.01%	2544
2016 Q2	–	Sell	-24,720	Closed	-$1.25M	–	3398
2016 Q1	$1.25M	Hold	24,720	–	–	﹤0.01%	2209
2015 Q4	$1.25M	Buy	+24,720	New	+$1.26M	﹤0.01%	2493

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

D.E. Shaw & Co's GSK Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in GSK (GSK) in Q2 2026: 1,019,449 shares worth $53.4M. The stake represents 0.03% of the portfolio and ranks #726 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in GSK as recently as Q4 2025.

D.E. Shaw & Co first reported a position in GSK in Q2 2013 and has held it in 30 quarters since. The position peaked at $81.6M in Q2 2015. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

D.E. Shaw & Co held 1,019,449 shares of GSK worth $53.4M as of Q2 2026.
GSK was a new D.E. Shaw & Co position in Q2 2026.
GSK made up 0.03% of D.E. Shaw & Co's portfolio in Q2 2026, its #726 holding.
D.E. Shaw & Co first reported a position in GSK in Q2 2013 and has held it in 30 quarters since.
D.E. Shaw & Co's GSK position peaked at $81.6M in Q2 2015.
1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.